Nebulized nitric oxide/nucleophile adduct reduces chronic pulmonary hypertension

Cardiovascular Research

Volumn 31, Issue 1, 1996, Pages 55-62

  Hampl, Václav ^a   Tristani Firouzi, Martin ^a   Hutsell, Thomas C ^b   Archer, Stephen L ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b University of Minnesota ^*  (United States)

Author keywords

Nitric oxide; NONOates; Pulmonary artery tone; Pulmonary hypertension; Rat, lung

Indexed keywords

DIETHYLENETRIAMINE; NITRIC OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY TONE; ARTICLE; CONTROLLED STUDY; INHALATIONAL DRUG ADMINISTRATION; NEBULIZATION; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT;

AEROSOLS; ANIMALS; CHRONIC DISEASE; DRUG COMBINATIONS; HYPERTENSION, PULMONARY; MALE; MONOCROTALINE; NITRIC OXIDE; PERFUSION; POLYAMINES; RATS; RATS, SPRAGUE-DAWLEY; VASOCONSTRICTION;

EID: 0029882023     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/0008-6363(95)00172-7     Document Type: Article

References (34)

1. Salvaterra CG, Rubin LJ. Investigation and management of pulmonary hypertension in chronic obstructive pulmonary disease. Am Rev Respir Dis 1993;148:1414-1417.
2. Frostell C, Fratacci M-D, Wain JC, Jones R, Zapol WM. Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation 1991;83:2038-2047.
3. Pepke-Zaba J, Higenbottam T, Dinh-Xuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilation in pulmonary hypertension. Lancet 1991;338:1173-1174.
4. Gerlach H, Rossaint R, Pappert D, Falke KJ. Time-course and dose-response of nitric oxide inhalation for systemic oxygenation and pulmonary hypertension in patients with adult respiratory distress syndrome. Eur J Clin Invest 1993;23:499-502.
5. Bigatello LM, Hurford WE, Kacmarek RM, Roberts JD, Zapol WM. Prolonged inhalation of low concentrations of nitric oxide in patients with severe adult respiratory distress syndrome - effects on pulmonary hemodynamics and oxygenation. Anesthesiology 1994;80: 761-770.
6. A/Q inequalities in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994;149:1482-1487.
7. Roberts JD, Polaner DM, Lang P, Zapol WM. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 1992;340:818-819.
8. Kinsella JP, Neish SR, Shaffer E, Abman SH. Low-dose inhalational nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 1992;340:819-820.
9. Girard C, Lehot JJ, Pannetier JC, Filley S, Ffrench P, Estanove S. Inhaled nitric oxide after mitral valve replacement with chronic pulmonary artery hypertension. Anesthesiology 1992;77:880-883.
10. Frostell CG, Blomqvist H, Hedenstierna G, Lundberg J, Zapol WM. Inhaled nitric oxide selectively reverses human hypoxic pulmonary vasoconstriction without causing systemic vasodilation. Anesthesiology 1993;78:427-435.
11. Rossaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993;328:399-405.
12. Rich GF, Murphy GD, Roos CM, Johns RA. Inhaled nitric oxide. Selective pulmonary vasodilation in cardiac surgical patients. Anesthesiology 1993;78:1028-1035.
13. Roberts JD, Lang P, Bigatello L, Vlahakes GJ, Zapol WM. Inhaled nitric oxide in congenital heart disease. Circulation 1993;87:447-453.
14. Adnot S, Kouyoumdjian C, Defouilloy C, Andrivet P, Sediame S, Herigault R, Fratacci MD. Hemodynamic and gas exchange responses to infusion of acetylcholine and inhalation of nitric oxide in patients with chronic obstructive lung disease and pulmonary hypertension. Am Rev Respir Dis 1993;148:310-316.
15. Journois D, Pouard P, Mauriat P, Malhére T, Vouhé P, Safran D. Inhaled nitric oxide as a therapy for pulmonary hypertension after operations for congenital heart defects. J Thorac Cardiovasc Surg 1994;107:1129-1135.
16. Adatia I, Lillihei C, Arnold JH, Thompson JE, Palazzo R, Fackler JC, Wessel DL. Inhaled nitric oxide in the treatment of postoperative graft dysfunction after lung transplantation. Ann Thorac Surg 1994;57:1311-1318.
17. Rich GF, Lowson SN, Johns RA, Daugherty MO, Uncles DR. Inhaled nitric oxide selectively decreases pulmonary vascular resistance without impairing oxygenation during one-lung ventilation in patients undergoing cardiac surgery. Anesthesiology 1994;80:57-62.
18. Winberg P, Lundell BPW, Gustafsson LE. Effect of inhaled nitric oxide on raised pulmonary vascular resistance in children with congenital heart disease. Br Heart J 1994;71:282-286.
19. Morley D, Keefer LK. Nitric oxide/nucleophile complexes: a unique class of nitric oxide-based vasodilators. J Cardiovasc Pharmacol 1993;22(Suppl. 7):S3-S9.
20. Kowaluk EA, Seth P, Fung H-L. Metabolic activation of sodium nitroprusside to nitric oxide in vascular smooth muscle. J Pharmacol Exp Ther 1992;262:916-922.
21. Seth P, Fung H-L. Biochemical characterization of a membrane-bound enzyme responsible for generating nitric oxide from nitroglycerin in vascular smooth muscle cells. Biochem Pharmacol 1993;46:1481-1486.
22. Kay JM, Keane PM, Suyama KL, Gauthier D. Angiotension converting activity and evolution of pulmonary vascular disease in rats with monocrotaline pulmonary hypertension. Thorax 1982;37:88-96.
23. Sugita T, Hyers TM, Dauber IM, Wagner WW, McMurtry IF, Reeves JT. Lung vessel leak precedes right ventricular hypertrophy in monocrotaline-treated rats. J Appl Physiol 1983;54:371-374.
24. Archer SL, Gebhard RL, Levine AS, Nelson DP, Prigge W, Cowan N, Weir EK. Exacerbation of monocrotaline pulmonary hypertension by a high-fat diet: association with increased lung levels of activated oxygen species. J Vasc Med Biol 1990;2:125-135.
25. Ye C, Rabinovitch M. Inhibition of elastolysis by SC-37698 reduces development and progression of monocrotaline pulmonary hypertension. Am J Physiol 1991;261:H1255-H1267.
26. Baker HJ, Lindsey JR, Weisbroth SH. Selected normative data. In: Baker HJ, Lindsey JR, Weisbroth SH, eds. The Laboratory Rat. II. Research Applications. New York: Academic Press, 1980:257-258.
27. Hampl V, Archer SL, Nelson DP, Weir EK. Chronic EDRF inhibition and hypoxia: effects on pulmonary circulation and systemic blood pressure. J Appl Physiol 1993;75:1748-1757.
28. Braman RS, Hendrix SA. Nanogram nitrite and nitrate determination in environmental and biological materials by vanadium (III) reduction with chemiluminescence detection. Anal Chem 1989;61:2715-2718.
29. Fulton RM, Hutchinson EC, Jones AM. Ventricular weight in cardiac hypertrophy. Br Heart J 1952;14:413-420.
30. Archer SL, Shultz PJ, Warren JB, Hampl V, DeMaster EG. Preparation of standards and measurement of nitric oxide, nitroxyl, and related oxidation products. Methods: a Companion to Methods in Enzymology 1995;7:21-34.
31. Martin W, Villani GM, Jothianandan D, Furchgott RF. Selective blockade of endothelium-dependent and glyceryl trinitrate-induced relaxation by hemoglobin and by methylene blue in the rabbit aorta. J Pharmacol Exp Ther 1985;232:708-716.
32. Zhou KR, Lai YL. Capsaicin pretreatment attenuates monocrotaline-induced ventilatory dysfunction and pulmonary hypertension. J Appl Physiol 1993;75:2781-2788.
33. Vanderford PA, Wong J, Chang R, Keefer LK, Soifer SJ, Fineman JR. Diethylamine/nitric oxide (NO) adduct, an NO donor, produces potent pulmonary and systemic vasodilation in intact newborn lambs. J Cardiovasc Pharmacol 1994;23:113-119.
34. Reeves JT, Groves BM. Approach to the patient with pulmonary hypertension. In: Weir EK, Reeves JT, eds. Pulmonary Hypertension. Mount Kisco: Futura, 1984:1-44.